ABT Misses Earnings, Shares Underperform Despite Growth Bets

Abbott Laboratories (ABT) reported Q4 2025 earnings on January 22, 2026, with revenue rising 4.4% year-over-year to $11.46 billion, though below the $11.8 billion consensus. Earnings per share (EPS) plummeted 80.8% to $1.02, missing estimates of $1.49. Guidance for 2026 organic sales growth of 6.5%-7.5% and adjusted EPS of $5.55-$5.80 aligns with expectations but reflects cautious optimism amid near-term challenges.

Revenue

Medical Devices led with $5.67 billion in revenue, driven by double-digit growth in structural heart and EPD, while Diagnostics contributed $2.46 billion. Nutrition and Established Pharmaceuticals added $1.94 billion and $1.38 billion respectively, though Nutrition faced market share losses. Total revenue reached $11.46 billion, reflecting disciplined execution and strategic investments in high-growth areas.

Earnings/Net Income

Net income contracted sharply to $1.78 billion ($1.02 EPS) in Q4 2025, down from $9.23 billion ($5.33 EPS) in Q4 2024. The EPS decline reflects significant net income contraction despite long-term profitability resilience.

Post-Earnings Price Action Review

The strategy of buying ABT shares post-revenue growth and holding for 30 days underperformed, with a CAGR of 0.65%, lagging the benchmark by 69.83%. A maximum drawdown of 22.99% and a Sharpe ratio of 0.03 underscored the high-risk, low-reward profile of the strategy.

CEO Commentary

CEO Robert Ford emphasized innovation in Diabetes Care (CGM sales up 12%) and Medical Devices, while acknowledging Nutrition’s challenges. Strategic moves like the Exact Sciences acquisition and new product launches aim to reignite growth in H2 2026.

Guidance

Abbott projected 2026 organic sales growth of 6.5%-7.5% and adjusted EPS of $5.55-$5.80, driven by margin expansion and disciplined cost management. The CFO highlighted favorable FX impacts and a 15%-16% tax rate, with Nutrition’s recovery expected in the second half.

Additional News

Abbott secured FDA approval for its Volt pulsed ablation device, expanding its cardiovascular portfolio. The company acquired Exact Sciences, entering the cancer diagnostics market, and announced a 7% dividend increase amid economic headwinds. Leadership remains focused on R&D and strategic growth in diabetes and structural heart segments.